VIDEO: Luminate blocks integrin receptors, reduces oxidative stress

VANCOUVER, British Columbia — At the American Society of Retina Specialists meeting, Peter K. Kaiser, MD, reviews differences between Luminate (risuteganib, Allegro), which decreases oxidative stress from diabetes by blocking integrin receptors, and Avastin (bevacizumab, Genentech), which works farther downstream in the oxidative pathway, at the level of inflammation and vascular permeability.

Full Story →